Physician profile
Daniel A Ramirez
NPI 1174536593
$9,896.46
in general payments reported to CMS, 2019-2025
36 companies · $1,762 in 2025
The $1,762 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $717 · 2021: $1,475 · 2022: $1,816 · 2023: $1,977 · 2024: $987 · 2025: $1,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,725.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,580.50 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,611.53 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $1,095.67 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Genzyme Corporation | $684.23 | 2019-2024 | |
| Genentech USA, INC. | $504.56 | 2019-2025 | Xolair |
| Csl Behring | $328.80 | 2021-2025 | Hizentra, Andembry |
| Optinose US, INC. | $253.05 | 2019-2023 | |
| Alk-Abello, INC | $251.85 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Kaleo, INC. | $235.84 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.46 | 2021-2023 | Spiriva Respimat |
| Ars Pharmaceuticals Operations, INC. | $216.35 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $202.18 | 2025 | |
| Amgen INC. | $182.93 | 2021-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $160.87 | 2021-2025 | |
| Grifols USA, LLC | $151.35 | 2021-2023 | Xembify |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $136.60 | 2023 | Stelara |
| Genentech, INC. | $128.64 | 2019 | |
| Incyte Corporation | $100.00 | 2022-2023 | Opzelura |
| Pfizer INC. | $98.78 | 2022 | |
| Octapharma USA, INC. | $92.00 | 2022-2024 | Cutaquig |
| Regeneron Pharmaceuticals, INC. | $87.36 | 2023 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $82.35 | 2020-2021 | |
| Greer Laboratories, INC. | $79.36 | 2024-2025 | Oralair |
| Sunovion Pharmaceuticals INC. | $53.79 | 2019 | |
| Pharming Healthcare, INC. | $51.68 | 2023-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $49.84 | 2020-2022 | |
| Galderma Laboratories, L.P. | $37.09 | 2025 | Nemluvio |
| Ionis Pharmaceuticals, INC. | $31.80 | 2025 | Dawnzera |
| Shire North American Group INC | $31.77 | 2019 | |
| Lilly USA, LLC | $29.99 | 2025 | Ebglyss |
| Leo Pharma INC. | $28.56 | 2024 | Adbry |
| Hikma Pharmaceuticals USA | $23.77 | 2025 | Ryaltris |
| Verona Pharma, INC. | $19.21 | 2025 | Ohtuvayre |
| Uswm, LLC | $17.00 | 2021 | |
| Aimmune Therapeutics, INC. | $16.68 | 2022 | |
| Organon LLC | $6.02 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.